Infection with alternate frequencies of SARS-CoV-2 vaccine boosting for patients undergoing antineoplastic cancer treatments
Townsend J, Hassler H, Emu B, Dornburg A. Infection with alternate frequencies of SARS-CoV-2 vaccine boosting for patients undergoing antineoplastic cancer treatments. Journal Of The National Cancer Institute 2023, 115: 1626-1628. PMID: 37599438, PMCID: PMC10699797, DOI: 10.1093/jnci/djad158.Peer-Reviewed Original ResearchConceptsReinfection riskAntineoplastic therapyAntibody dataSARS-CoV-2 infectionSARS-CoV-2 vaccinesChemotherapy-immunotherapy combinationsPfizer-BioNTech BNT162b2COVID-19 vaccinationHigh infection riskFrequent boostingRituximab therapyBreakthrough infectionsVaccination scheduleAntibody levelsBooster scheduleVaccination frequencyImmune responseAdditional interventionsReduced riskHigh riskHormonal treatmentGeneral populationNecessitating assessmentPatientsInfection riskInfection by SARS‐CoV‐2 with alternate frequencies of mRNA vaccine boosting
Townsend J, Hassler H, Dornburg A. Infection by SARS‐CoV‐2 with alternate frequencies of mRNA vaccine boosting. Journal Of Medical Virology 2023, 95: e28461. PMID: 36602045, DOI: 10.1002/jmv.28461.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Anti-spike IgG antibodiesWaning of antibodiesVaccine boostingBooster vaccinationBreakthrough infectionsAntibody levelsIgG antibodiesMRNA vaccinesProbability of infectionInfectionEndemic transmissionIndividual infectionsPredominant variantCOVID-19 pandemicMessenger RNAAntibodiesDisease spreadBNT162b2HospitalizationMorbidityVaccinationWidespread uptakeVaccineMortality